Provider Briefing: Vijoice Access in 2026

For providers managing patients with PIK3CA-Related Overgrowth Spectrum (PROS), Vijoice (Alpelisib) remains the only FDA-approved systemic treatment option. While the drug is not currently listed on any formal shortage database, the access challenges your patients face are real and persistent. Understanding the current distribution model, insurance landscape, and available support resources is essential for keeping patients on therapy.

This briefing covers what prescribers need to know about Vijoice 50 Mg 28 Day availability, cost, and access strategies in 2026.

Timeline: Vijoice Approval and Availability

• April 2022: FDA grants accelerated approval to Vijoice (Alpelisib) for adults and pediatric patients ≥2 years with severe PROS requiring systemic therapy, based on EPIK-P1 expanded access data.
• 2023-2024: Vijoice establishes its position as the primary systemic treatment for PROS, replacing off-label Sirolimus as the first-line option in many centers.
• 2024: FDA approves Vijoice oral granules (50 mg packets) as an additional dosage form for patients who cannot swallow tablets.
• 2025: Updated prescribing information includes dose escalation guidance for pediatric patients ≥6 years (50 mg → 125 mg after 24 weeks).
• 2026: Vijoice remains available through specialty pharmacies. No formal supply shortage reported.

Prescribing Implications

Dosing Overview

• Pediatric (2 to <18 years): Initial dose 50 mg once daily with food. Consider dose increase to 125 mg once daily for patients ≥6 years after 24 weeks if clinical or radiological response optimization is warranted.
• Adult (≥18 years): 250 mg once daily with food.
• Dosage forms: 50 mg, 125 mg, and 200 mg film-coated tablets; 50 mg oral granule packets. Granules are for 50 mg doses only—do not use multiple packets for higher doses.

Key Monitoring Requirements

• Blood glucose: Monitor fasting glucose before initiation and periodically during treatment. Severe hyperglycemia (including HHNKS and ketoacidosis, observed in the oncology setting) is a known risk.
• Skin reactions: Monitor for severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome.
• Pulmonary: Assess for signs of pneumonitis. Permanently discontinue Vijoice if confirmed.
• GI: Monitor for severe diarrhea and colitis, which can lead to dehydration and acute kidney injury.
• Fertility: Counsel patients of reproductive potential regarding contraception requirements.

Drug Interactions to Review

• BCRP inhibitors (cyclosporine, eltrombopag): Avoid concomitant use—may increase Alpelisib exposure and toxicity risk.
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort): May decrease Alpelisib efficacy.
• CYP2C9 substrates (warfarin): May increase substrate exposure; monitor closely.

For detailed interaction information, see Vijoice drug interactions: what to avoid.

Current Availability Picture

Vijoice is not on the FDA or ASHP shortage lists as of early 2026. Supply from Novartis appears stable. The access challenges providers and patients encounter are primarily related to:

• Limited specialty pharmacy distribution: Vijoice is not available at retail pharmacies. It must be dispensed through specialty pharmacies equipped to handle prior authorization, cold chain logistics, and patient coordination.
• Prior authorization delays: Most payers require extensive documentation including confirmed PIK3CA gene mutation and physician attestation of severe PROS requiring systemic therapy. Initial authorization can take 1-3 weeks.
• Patient unfamiliarity with specialty pharmacy processes: Many PROS patients (or their caregivers) are navigating specialty pharmacy workflows for the first time and may interpret process delays as supply problems.

Cost and Access Considerations

The wholesale acquisition cost for Vijoice is approximately $31,754 per 28-day supply regardless of tablet strength. This price point makes financial assistance critical for most patients:

• Novartis Oncology Universal Co-Pay Program: Commercially insured patients may pay as little as $0/month, with Novartis covering up to $15,000/year. Enrollment: 1-877-577-7756 or Copay.NovartisOncology.com.
• Novartis Patient Assistance Foundation (NPAF): Free medication for eligible uninsured or underinsured patients. Enrollment: 1-800-277-2254 or pap.novartis.com.
• Patient Access Network Foundation (PAN): May provide copay assistance depending on available funding.

Proactively connecting patients with these programs at the time of prescribing—rather than after an access problem arises—can prevent treatment gaps.

Tools and Resources for Providers

Medfinder for Providers offers a streamlined way to help patients locate pharmacies with Vijoice in stock. Rather than directing patients to call pharmacies individually, you can reference Medfinder as a real-time availability tool.

Additional provider resources:

• Novartis HCP site: vijoice-hcp.com — prescribing information, dosing guides, access program details
• Novartis Field Reimbursement Managers: Can assist with prior authorization strategies and appeals
• ClinicalTrials.gov: For patients interested in investigational PROS therapies (e.g., Miransertib)

For a practical guide on helping patients navigate access, see how to help your patients find Vijoice in stock.

Looking Ahead

Several developments are worth monitoring:

• Confirmatory trial data: Vijoice was approved under accelerated approval. Continued approval is contingent upon verification of clinical benefit in confirmatory trials. Providers should stay informed about upcoming data readouts.
• Dose optimization studies: Evolving data on pediatric dose escalation (50 mg → 125 mg) may change treatment patterns for patients who have been on the starting dose long-term.
• Pipeline therapies: AKT inhibitors and other PI3K pathway-targeting agents in development could eventually expand the treatment landscape for PROS.
• No generic timeline: There is currently no generic version of Alpelisib available or imminent, meaning brand-name Vijoice will remain the sole option for the foreseeable future.

Final Thoughts

Vijoice 50 Mg 28 Day is available but operates entirely within the specialty pharmacy ecosystem. The most effective thing providers can do is anticipate access barriers at the time of prescribing: initiate prior authorization early, connect patients with Novartis financial assistance, assign a specialty pharmacy, and set expectations about the timeline.

For patient-facing resources you can share, see our articles on how to find Vijoice in stock and how to save money on Vijoice. For the provider-focused access guide, visit Medfinder for Providers.